BioChimPharm Celebrates a Year of Groundbreaking Achievements in 2023

BioChimPharm, a leader in Georgia's biopharmaceutical industry, has marked 2023 with a series of significant achievements, underscoring its commitment to innovation and excellence.

This year, the company reached a historic milestone by obtaining GMP (Good Manufacturing Practice) certification for their pioneering manufacturing facility, established in 1934. This achievement positions BioChimPharm as the first company in Transcaucasia, and globally, to produce phages on an industrial scale in compliance with European standards.

In a significant development for both local and international healthcare markets, BioChimPharm has reintroduced its life-saving phage preparations, now aligned with European standards, since September 15th. The company continues to focus on creating innovative products and expanding its export territories, demonstrating its dedication to advancing global health solutions.

2023 also saw BioChimPharm taking a bold initiative in the establishment of the Georgian Biopharmaceutical Cluster. Supported by key partners, this cluster aims to develop the phage and herbal medicine industries, with the goal of establishing Georgia as a significant player on the world biopharmaceutical map. In November, during the World Antibiotic Resistance Awareness Week, BioChimPharm hosted a large-scale international biopharmaceutical conference in Tbilisi, bringing together various stakeholders to work towards the cluster's objectives.

In recognition of the efforts of those dedicated to phage technology and the fight against antibiotic resistance, BioChimPharm introduced the Phage Award. This award is a testament to the company's commitment to acknowledging and supporting groundbreaking work in this field.

BioChimPharm's efforts and innovations have not gone unnoticed on the global stage. The World Economic Forum (Davos) recognized phage technology as one of the top 10 revolutionary technologies for 2023, a commendation that coincides with Georgia's recent achievement of being granted EU candidate status.

These accomplishments of 2023 are a reflection of the hard work and dedication of the BioChimPharm team, alongside the invaluable support of their partners. As the company looks towards 2024, it does so with a vision for continued groundbreaking developments in the biopharmaceutical industry.